Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lipiodol

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Lipiodol. Displaying page 1 of 1.
    EudraCT Number: 2017-004859-22 Sponsor Protocol Number: UF9888 Start Date*: 2018-04-12
    Sponsor Name:University Hospital of Monptellier
    Full Title: Treatment of hepatocellular carcinoma on child cirrhosis A/B7 by intra-arterial injection of a Lipiodol and Idarubicin emulsion : a multicentric single-arm phase II study
    Medical condition: The research hypothesis is that hepatic locoregional treatment without embolization, using a more cytotoxic anticancer molecule (Idarubicin) than those conventionally used, would be more effective.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004429-34 Sponsor Protocol Number: 2017.lipiodol.flush Start Date*: 2018-02-15
    Sponsor Name:UZ Brussel
    Full Title: Histological and Transcriptional Changes caused by Endometrial Flushing with Lipiodol: A Cross Over Study.
    Medical condition: Female subfertility
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10042392 Subfertility (female) LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002206-10 Sponsor Protocol Number: APHP190891 Start Date*: 2020-07-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A prospective study of the safety and efficacy of the use of a Lipiodol Emulsion for the embolization of inflammatory hypervascularizations observed in patients with articular or abarticular pain i...
    Medical condition: Adult patients with articular or abarticular intractable pain in the knee
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001362-15 Sponsor Protocol Number: 7773 Start Date*: 2019-12-05
    Sponsor Name:University Hospital of Montpellier
    Full Title: Hepatocellular carcinoma less than 3 cm treated with percutaneous tumour destruction: multicentric phase 2 trial assessing the impact of idarubicin-lipiodol intra-arterial chemotherapy on hepatic r...
    Medical condition: The research hypothesis is that hepatic locoregional treatment with idarubicin and lipiodol would be an effective adjuvant therapy of hepatocellular carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001257-31 Sponsor Protocol Number: TACTIDA Start Date*: 2021-08-25
    Sponsor Name:Department of Pharmaceutical Biosciences, Uppsala University
    Full Title: An open, single center two-step trial (A+B), comparing the safety and tolerability of idarubicin 10 mg and 15 mg after separate single hepatic intra-arterial injections of a drug formulation based ...
    Medical condition: intermediate stage hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006478-79 Sponsor Protocol Number: SX-PHCC-001 Start Date*: 2007-07-16
    Sponsor Name:SIRTEX Medical Europe
    Full Title: Study of Radioembolization (RE) with SIR-Spheres® versus Transarterial Chemoembolisation (TACE) in patients with unresectable primary Hepatocellular Carcinoma. A comparative, prospective, randomise...
    Medical condition: Unresectable primary hepatocellular carcinoma (pHCC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000163-25 Sponsor Protocol Number: HE2006 Start Date*: 2005-08-04
    Sponsor Name:Research and Enterprise, University of Birmingham
    Full Title: Proteomics and Pharmacokinetics of Adriamycin Following Different Techniques for Chemoembolisation of Hepatocellular Carcinoma (PPATCH) Trial
    Medical condition: Hepatocellular cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004153-24 Sponsor Protocol Number: NL62838.029.18 Start Date*: 2019-07-30
    Sponsor Name:Amsterdam UMC - location Vrije Universiteit Amsterdam
    Full Title: Tubal flushing with oil-based contrast during HSG in subfertile women: Is early flushing effective and cost-effective as compared to delayed flushing?
    Medical condition: The research population consists of infertile women aged between 18 and 39 years of age, who have a spontaneous menstrual cycle and with a perceived low risk for tubal pathology, undergoing fertili...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004192-12 Sponsor Protocol Number: NL66079.029.18 Start Date*: 2019-08-05
    Sponsor Name:Amsterdam UMC, location VU medical Center
    Full Title: Oil- based versus water-based contrast media for hysterosalpingography (HSG) in infertile women with unevaluated indications: a randomized controlled trial
    Medical condition: The research population consists of infertile couples who have tried to conceive for at least 12 months, or have oligo- or anovulation. We will focus on women with ovulation disorders, or at high r...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023411-33 Sponsor Protocol Number: ONC-2009-002 Start Date*: 2010-11-03
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: A phase II, randomized, double-blind, placebo controlled trial of Sorafenib as adjuvant treatment for hepatocellular carcinoma after TACE-based treatments.
    Medical condition: hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000270-28 Sponsor Protocol Number: NL75171.058.20 Start Date*: 2022-06-30
    Sponsor Name:Leiden University Medical Center
    Full Title: Selective Indocyanine Green Injection of a Segmental Hepatic Artery Followed by Near-Infrared Fluorescence Guided Anatomical Liver Resection: A Feasibility Study
    Medical condition: Hepatocellular carcinoma, hepatic adenoma, intrahepatic cholangiocarcinoma, colorectal liver metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001244-56 Sponsor Protocol Number: LiCTOP-C-001 Start Date*: 2013-07-23
    Sponsor Name:Department of Pharmacy, Uppsala University
    Full Title: An open, multicenter, single dose, parallel study, evaluating the pharmacokinetics of doxorubicin and its active metabolite (doxorubicinol) after a hepatic intra-arterial injection of either a lipi...
    Medical condition: Intermediate hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005456-32 Sponsor Protocol Number: P051062 Start Date*: 2007-03-30
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Chimiothérapie intra-arterielle lipiodolée (CIAL) versus chimiothérapie systémique par gemcitabine et oxaliplatine (GEMOX) versus surveillance simple après résection ou destruction des carcinomes h...
    Medical condition: carcinome hépatocellulaire sur cirrhose
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051571 carcinome hépatocellulaire sur cirrhose PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002135-30 Sponsor Protocol Number: NCT04379973 Start Date*: 2021-04-28
    Sponsor Name:Antwerp University Hospital (UZA)
    Full Title: Live birth after additional tubal flushing with oil-based contrast versus no additional flushing: a randomised, multicentre, parallel group pragmatic trial in infertile women with at least one pate...
    Medical condition: Infertility defined as lack of conception despite 12 months of unprotected intercourse, or three cycles of donor insemination without pregnancy or three ovulatory ovulation induction cycles without...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001477-14 Sponsor Protocol Number: HCC-P3-11-01 Start Date*: 2012-06-15
    Sponsor Name:MERIT MEDICAL SYSTEMS, INC.
    Full Title: Phase 3 Prospective,Randomized, blinded and controlled investigation of Hepasphere/Quadrasphere microspheres for delivery of doxorubicin for the treatment of hepatocellular cancer. This Study is Ph...
    Medical condition: Liver Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024722 Liver, cancer of, primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002163-26 Sponsor Protocol Number: PRI2017HUS7040 Start Date*: 2018-07-03
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: Pilot study on doxorubicin kinetic distribution during arterial chemoembolization
    Medical condition: hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003447-34 Sponsor Protocol Number: REQ-0000020479 Start Date*: 2019-04-03
    Sponsor Name:Hellenic Genitourinary Cancer Group (HGUCG)
    Full Title: Nivolumab plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC) not undergoing cystectomy: a phase II, randomized study
    Medical condition: muscle-invasive bladder cancer (MIBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003649-14 Sponsor Protocol Number: Bay73-4506/15982 Start Date*: 2013-01-30
    Sponsor Name:Bayer AG
    Full Title: A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) CZ (Completed) FR (Completed) HU (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 23:15:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA